Literature DB >> 8376482

High-performance liquid chromatographic analysis of tamoxifen, toremifene and their major human metabolites.

F Berthou1, Y Dréano.   

Abstract

The chromatographic behaviour of tamoxifen, toremifene and their major metabolites was investigated by reversed-phase high-performance liquid chromatography on four stationary phases. Two packings were the usual octadecylsilane type and the other two were octylsilane and octadecylsilane of the type specific for basic compounds. The results provide new insight into variations in selectivity with column type for drugs whose basic properties, owing to the presence of an ionizable nitrogen atom, make their chromatography difficult. The results allow an improvement of the separation of metabolites of tamoxifen and toremifene, two triphenylethylene drugs widely used for the treatment of breast cancer. A method is described for the identification and determination of metabolites formed by incubating the parent drugs with human liver microsomal preparations. The assay has been optimized for the identification and quantification of three major metabolites formed by N-oxidative demethylation of the side-chain, 4-hydroxylation of the aromatic ring and a side-chain deamination followed by hydroxylation. These catalytic activities involve cytochrome P450 enzymes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8376482     DOI: 10.1016/0378-4347(93)80478-m

Source DB:  PubMed          Journal:  J Chromatogr


  3 in total

Review 1.  Bioactivation of Selective Estrogen Receptor Modulators (SERMs).

Authors:  Tamara S Dowers; Zhi-Hui Qin; Gregory R J Thatcher; Judy L Bolton
Journal:  Chem Res Toxicol       Date:  2006-09       Impact factor: 3.739

2.  Characterization of the isomeric configuration and impurities of (Z)-endoxifen by 2D NMR, high resolution LC⬜MS, and quantitative HPLC analysis.

Authors:  Phyllis Elkins; Donna Coleman; Jason Burgess; Michael Gardner; John Hines; Brendan Scott; Michelle Kroenke; Jami Larson; Melissa Lightner; Gregory Turner; Jonathan White; Paul Liu
Journal:  J Pharm Biomed Anal       Date:  2013-07-24       Impact factor: 3.935

Review 3.  Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer.

Authors:  L R Wiseman; K L Goa
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.